HaemaLogiX Announces Positive Final Results from KappaMab Combination Phase IIb Myeloma Trial
- Written by PR Newswire
- Significant improvement in Overall Response Rate (83%) compared with matched case control group (45%).
- Significant overall survival advantage, with a 46% reduction in the risk of death.
- Excellent safety profile and significant efficacy bolster HaemaLogiX's plan to progress further KappaMab / standard of care combination studies.
SYDNEY, June 29, 2023...